)
Visual
test
Molecure
Molecure (MOC) investor relations material
Molecure Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary10 Mar, 2026
Executive summary
Report covers the period from 01.01.2025 to 31.12.2025, with comparative data for 2024.
Main activity is R&D of small-molecule drugs for high unmet clinical needs, especially oncology and respiratory diseases.
The company operates under a business model with delayed revenue recognition, resulting in a net loss for the year.
No material uncertainty regarding going concern; management expects continued operations for at least 12 months.
Financial highlights
Operating revenue: PLN 6.52 million in 2025, up from PLN 2.15 million in 2024.
Net loss: PLN 15.69 million in 2025, significantly reduced from PLN 31.53 million in 2024.
Operating loss: PLN 16.56 million in 2025, improved from PLN 32.33 million in 2024.
Cash and equivalents at year-end: PLN 16.35 million (down from PLN 17.90 million in 2024).
Total assets: PLN 94.43 million at 31.12.2025 (down from PLN 113.44 million at 31.12.2024).
Equity: PLN 87.45 million at year-end (down from PLN 103.13 million in 2024).
Basic and diluted loss per share: PLN -0.76 (improved from PLN -1.56 in 2024).
Outlook and guidance
Focus remains on advancing clinical-stage programs and optimizing cost structure.
Strategic shift to concentrate resources on key clinical programs with highest commercial potential.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Molecure
- OATD01 and OATD02 clinical progress, cost control, and active partnering drive outlook.MOC
Q4 202429 Nov 2025 - Net loss narrowed to PLN -14.0m as clinical programs advanced and cost base was reduced.MOCQ3 202531 Oct 2025
- Net loss narrowed to PLN 8.52 million in H1 2025, with strong cash reserves and cost optimization.MOCQ2 202530 Sep 2025
- Net loss of PLN 14.6 million in H1 2024, with robust equity and ongoing R&D investment.MOCQ2 202413 Jun 2025
- Net loss deepened to PLN 20.83m as Molecure advanced clinical and mRNA drug programs.MOCQ3 202413 Jun 2025
- OATD-01 and OATD-02 drive Molecure's growth, targeting major unmet needs in inflammation and cancer.MOCInvestor Presentation13 Jun 2025
- $32M YKL40 deal and pipeline focus position Molecure for growth in high-value disease markets.MOCInvestor Presentation13 Jun 2025
- Q1 2025 saw Molecure deepen R&D, post a PLN 5.18m net loss, and boost cash to PLN 40.66m.MOCQ1 20256 Jun 2025
Next Molecure earnings date
Q1 202630 Apr, 2026
Molecure
Next Molecure earnings date
Q1 202630 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage